South Korea's CTC Bio out licenses drug-delivery technology to Swiss-based Ferring

SINGAPORE--South Korea's CTC Bio has out licensed rights to its drug-delivery technology to Swiss-based Ferring Pharmaceuticals, with the two companies to collaborate and develop in-vitro and in-vivo tests of drug prototypes.

The deal includes the usual up-front, milestone and royalty terms, but the dollar amounts were not disclosed.

Ferring said it planned to use the collaboration to develop oral versions of its peptide drugs, including Minirin (desmopressin and lyophilisate) versions.

CTC Bio said its novel oral drug-delivery technology enables production of hydrophilic macromolecules such as peptides in oral forms.

- read the Ferring release